相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CD38 knocKout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
Mark Gurney et al.
HAEMATOLOGICA (2022)
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
Kristen Fousek et al.
LEUKEMIA (2021)
Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma
Zachery Halford et al.
ANNALS OF PHARMACOTHERAPY (2021)
Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7
Christina Amatya et al.
MOLECULAR THERAPY (2021)
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
Renee Poels et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Preclinical development of CD126 CAR-T cells with broad antitumor activity
Ameet K. Mishra et al.
BLOOD CANCER JOURNAL (2021)
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma
Anupama Doraiswamy et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)
Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma
Vita Golubovskaya et al.
CANCERS (2021)
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis
Lisa C. Holthof et al.
CLINICAL CANCER RESEARCH (2021)
Pharmacologic Control of CAR T Cells
Benjamin Caulier et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models
Dina Schneider et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
CAR-T cell therapy: current limitations and potential strategies
Robert C. Sterner et al.
BLOOD CANCER JOURNAL (2021)
CAR T-cell therapy in multiple myeloma: more room for improvement
Phaik Ju Teoh et al.
BLOOD CANCER JOURNAL (2021)
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
Maxwell Y. Lee et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors
Nayoung Kim et al.
BMB REPORTS (2021)
Treatment Options for Triple-class Refractory Multiple Myeloma
Joseph Mikhael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Recent Advances in Allogeneic CAR-T Cells
Dong Wook Kim et al.
BIOMOLECULES (2020)
Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Aviad Ben-Shmuel et al.
FRONTIERS IN IMMUNOLOGY (2020)
Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
Jesus G. Berdeja et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Hanren Dai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Overcoming hypoxia-induced functional suppression of NK cells
Kristen Solocinski et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
Kellsye P. Fabian et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Adaptor CAR Platforms-Next Generation of T Cell-Based Cancer Immunotherapy
Claudia Arndt et al.
CANCERS (2020)
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
Sherly Mardiana et al.
FRONTIERS IN ONCOLOGY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
Yvette Robbins et al.
ELIFE (2020)
The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies
Andriy Zhylko et al.
CANCERS (2020)
Mechanisms of immune escape in the cancer immune cycle
Sha Tang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Nirav N. Shah et al.
NATURE MEDICINE (2020)
CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies
Malgorzata Bobrowicz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia
Valentina Griggio et al.
FRONTIERS IN IMMUNOLOGY (2020)
Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance
Madeleine R. Berendsen et al.
CANCERS (2020)
CAR T-Cells in Multiple Myeloma Are Ready for Prime Time
Paula Rodriguez-Otero et al.
JOURNAL OF CLINICAL MEDICINE (2020)
4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells
Qiang Dai et al.
FRONTIERS IN IMMUNOLOGY (2020)
Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring Universal Donor T Cells
Cynthia Perez et al.
FRONTIERS IN IMMUNOLOGY (2020)
Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
Ji-Yoon Noh et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting
Stefan Grote et al.
ONCOIMMUNOLOGY (2020)
Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Updated Analysis of the ELIANA Clinical Trial
Stephan A. Grupp et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth
Sarah Oelsner et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Mohamed-Reda Benmebarek et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia
Padma Akkapeddi et al.
LEUKEMIA (2019)
Regulatory T cells in cancer immunosuppression - implications for anticancer therapy
Yosuke Togashi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
Nirav N. Shah et al.
FRONTIERS IN ONCOLOGY (2019)
CAR-T efficacy: is conditioning the key?
Sattva S. Neelapu
BLOOD (2019)
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
Ankit J. Kansagra et al.
BONE MARROW TRANSPLANTATION (2019)
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221
Anna V. Tinker et al.
CLINICAL CANCER RESEARCH (2019)
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Katrin Mestermann et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
Richard Lemal et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells
Mattias Carlsten et al.
FRONTIERS IN IMMUNOLOGY (2019)
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
Xinjie Xu et al.
FRONTIERS IN IMMUNOLOGY (2019)
Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
Katsiaryna Marhelava et al.
CANCERS (2019)
Tumor-Associated Macrophages in Hematologic Malignancies: New Insights and Targeted Therapies
Amy J. Petty et al.
CELLS (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors
Yong Gu Lee et al.
CANCER RESEARCH (2019)
Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
Deepu Madduri et al.
BLOOD (2019)
A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial
Chenggong Li et al.
BLOOD (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia
Steven M. Bair et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
Mark B. Geyer et al.
JCI INSIGHT (2019)
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Hakan Koksal et al.
BLOOD ADVANCES (2019)
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
E. Liu et al.
LEUKEMIA (2018)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia
Todd A. Fehniger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee et al.
BLOOD (2018)
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
Miriam Y. Kim et al.
CELL (2018)
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Andreas T. Bjorklund et al.
CLINICAL CANCER RESEARCH (2018)
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
Haneen Shalabi et al.
HAEMATOLOGICA (2018)
CD19 CAR-T cell therapy for relapsed / refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
Li-Na Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions
Sang Yun Lee et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity
Lucas Ferrari de Andrade et al.
SCIENCE (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
Haneen Shalabi et al.
HAEMATOLOGICA (2018)
Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
Zhongzhen Yi et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
Chimeric Antigen Receptor-T Cells with 4-1BB Co-Stimulatory Domain Present a Superior Treatment Outcome than Those with CD28 Domain Based on Bioinformatics
Qi Zhong et al.
ACTA HAEMATOLOGICA (2018)
Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function
Steven D. Scoville et al.
BLOOD (2018)
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Joy Hsu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
Alexander I. Salter et al.
SCIENCE SIGNALING (2018)
Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy
Melanie D. Whittington et al.
JAMA ONCOLOGY (2018)
Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy Reply
Inmaculada Hernandez et al.
JAMA ONCOLOGY (2018)
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
Michael M. Boyiadzis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Kim Margolin et al.
CLINICAL CANCER RESEARCH (2018)
CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk et al.
BLOOD (2018)
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas
Irene Scarfo et al.
BLOOD (2018)
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
Friederike Braig et al.
BLOOD (2017)
An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia
S. P. Koerner et al.
LEUKEMIA (2017)
CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies
Alexandra Martyniszyn et al.
HUMAN GENE THERAPY (2017)
Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
Maria Carmen Ochoa et al.
IMMUNOLOGY AND CELL BIOLOGY (2017)
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
Cameron J. Turtle et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immunotherapy in hematologic malignancies: past, present, and future
Annie Im et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
James N. Kochenderfer et al.
MOLECULAR THERAPY (2017)
Engineering Natural Killer Cells for Cancer Immunotherapy
Katayoun Rezvani et al.
MOLECULAR THERAPY (2017)
A Milestone for CAR T Cells
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Chimeric Antigen Receptor T Cells in Hematologic Malignancies
Brandon R. Shank et al.
PHARMACOTHERAPY (2017)
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy
Zachary B. Davis et al.
SEMINARS IN IMMUNOLOGY (2017)
Mechanisms of Immune Tolerance in Leukemia and Lymphoma
Emily K. Curran et al.
TRENDS IN IMMUNOLOGY (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL.
Saar Gill et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase 1 clinical trial of adoptive immunotherapy using off-the-shelf activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia
Michael Boyiadzis et al.
CYTOTHERAPY (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
Loredana Ruggeri et al.
HAEMATOLOGICA (2016)
CAR-modified T-cell therapy for cancer: an updated review
Mostafa Haji-Fatahaliha et al.
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY (2016)
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
Loredana Ruggeri et al.
HAEMATOLOGICA (2016)
Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
Pavel Otahal et al.
ONCOIMMUNOLOGY (2016)
Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies
Chuang Sun et al.
BLOOD (2016)
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
Marco Ruella et al.
CLINICAL CANCER RESEARCH (2016)
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Yongxian Hu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Targeting natural killer cells in cancer immunotherapy
Camille Guillerey et al.
NATURE IMMUNOLOGY (2016)
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
Daniel T. Harris et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Repression of GSK3 restores NK cell cytotoxicity in AML patients
Reshmi Parameswaran et al.
NATURE COMMUNICATIONS (2016)
IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
Peter S. Kim et al.
ONCOTARGET (2016)
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
Eugenia Zah et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab
Gregory A. Rufener et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia
Emily M. McWilliams et al.
ONCOIMMUNOLOGY (2016)
Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report
Wen-ying Zhang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
Kathryn Lagrue et al.
BLOOD (2015)
Complex Karyotype is a Stronger Predictor Than Del(17p) for an Inferior Outcome in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients Treated With Ibrutinib-Based Regimens
Philip A. Thompson et al.
CANCER (2015)
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma
Don M. Benson et al.
CLINICAL CANCER RESEARCH (2015)
Heart Failure and Asymptomatic Left Ventricular Systolic Dysfunction in Lymphoma Survivors Treated With Autologous Stem-Cell Transplantation: A National Cross-Sectional Study
Klaus Murbraech et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chimeric antigen receptor T cells for ALL
Persis J. Amrolia et al.
LANCET (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Role of tumor-associated macrophages in hematological malignancies
Yoshihiro Komohara et al.
PATHOLOGY INTERNATIONAL (2015)
Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma
Fei Chen et al.
MEDICAL SCIENCE MONITOR (2015)
Target Antigen Density Governs the Efficacy of Anti-CD20-CD28-CD3 ζ Chimeric Antigen Receptor-Modified Effector CD8+ T Cells
Keisuke Watanabe et al.
JOURNAL OF IMMUNOLOGY (2015)
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Holbrook E. Kohrt et al.
BLOOD (2014)
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Stephan Stilgenbauer et al.
BLOOD (2014)
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
Brian Philip et al.
BLOOD (2014)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells
Yao Wang et al.
CLINICAL IMMUNOLOGY (2014)
The targeting of immunosuppressive mechanisms in hematological malignancies
M. H. Andersen
LEUKEMIA (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The inducible caspase-9 suicide gene system as a safety switch to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
Tessa Gargett et al.
FRONTIERS IN PHARMACOLOGY (2014)
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies
Kim De Veirman et al.
FRONTIERS IN ONCOLOGY (2014)
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Torsten Tonn et al.
CYTOTHERAPY (2013)
Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients
Katrin S. Reiners et al.
MOLECULAR THERAPY (2013)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain et al.
CANCER DISCOVERY (2013)
Novel immune modulators used in hematology: impact on NK cells
Stephanie Krieg et al.
FRONTIERS IN IMMUNOLOGY (2013)
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Norbert Vey et al.
BLOOD (2012)
T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells
K. Mihara et al.
LEUKEMIA (2012)
The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin's and non-Hodgkin's lymphoma survivors: a systematic review
Simone Oerlemans et al.
ANNALS OF HEMATOLOGY (2011)
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
Xiuli Wang et al.
BLOOD (2011)
Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
Maria R. Parkhurst et al.
CLINICAL CANCER RESEARCH (2011)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
James N. Kochenderfer et al.
BLOOD (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Health Status and Quality of Life Among Non-Hodgkin Lymphoma Survivors
Sophia K. Smith et al.
CANCER (2009)
Activated T-cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin Lymphoma
Keichiro Mihara et al.
JOURNAL OF IMMUNOTHERAPY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Brian G. Till et al.
BLOOD (2008)
Battling the Hematological malignancies: The 200 years' war
Marshall A. Lichtman
ONCOLOGIST (2008)
Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma
A. Plonquet et al.
ANNALS OF ONCOLOGY (2007)
The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma
Jonathan D. Tward et al.
CANCER (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma
EC Moser et al.
BLOOD (2006)
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells
MA Pulè et al.
MOLECULAR THERAPY (2005)
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
L Gattinoni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
P Feugier et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Opinion - Immunotherapy and chemotherapy - a practical partnership
RA Lake et al.
NATURE REVIEWS CANCER (2005)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
CA Klebanoff et al.
TRENDS IN IMMUNOLOGY (2005)
Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults
O Hequet et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
